The Investigational Device Exemption (IDE) is the FDA’s regulatory mechanism that allows an unapproved medical device to be shipped and used in human clinical trials to collect safety and effectiveness data. Without an approved IDE (for Significant Risk devices) or proper IRB oversight (for Non-Significant Risk devices), you cannot legally begin most clinical studies in the United States.
While many MedTech startups focus only on getting the IDE application approved within the FDA’s 30-day review window, the real risk to your company often lies beyond the approval itself. The way you structure Clinical Trial Agreements (CTAs), protect your intellectual property, secure ownership of clinical data, and manage negotiations with research institutions can make or break your future 510(k) or PMA submission, and your company’s valuation.
At Crowley Law LLC, we bridge the gap between clinical necessity and corporate protection. We help MedTech startups build an IDE + Clinical Trial Strategy that goes far beyond basic FDA compliance. It protects your intellectual property, secures ownership of clinical data, and maximizes your company’s enterprise value.
The process of managing IDE-regulated clinical trials is not merely a regulatory hurdle; it is a complex intersection of administrative law, intellectual property, and high-stakes negotiation. Our approach focuses on three core areas:
In the life sciences sector, the way you manage external testing is closely scrutinized by potential partners, acquirers, and investors. Relying on informal agreements or failing to define data ownership can create significant due diligence red flags.
Careful management of your IDE-regulated clinical trials and clinical contracts provides several structural benefits to your startup:
A custom-tailored management of your IDE + Clinical Trial Strategy and clinical contracts provides several critical layers of protection:
Choosing the correct regulatory pathway influences your timeline, budget, and contractual needs. The distinction between SR and NSR devices is a fundamental starting point.
Feature | Significant Risk (SR) Device | Non-Significant Risk (NSR) Device |
Primary Function | Presents a potential for serious risk to the health, safety, or welfare of a subject. | Does not pose a significant risk to subjects. |
FDA Requirement | Requires formal IDE application submission and explicit FDA approval. | FDA approval not required; IRB acts as the surrogate overseer. |
IRB Approval | Requires both FDA approval AND local IRB approval at the testing site. | Requires only local IRB approval at the testing site. |
Examples | Implants, life-sustaining devices, high-risk diagnostics, novel surgical lasers. | Wearables, low-risk non-invasive diagnostics, and standard dental tools. |
Success in the clinical phase requires a specialized integration of healthcare regulations and intellectual property law. At Crowley Law LLC, we synthesize these distinct legal areas into a single, cohesive clinical strategy designed to safeguard your innovation. Key contractual components include:
Poorly drafted CTAs often leak value by granting hospitals co-ownership of data. To preserve your “Compliance Fortress,” we lock in these key terms:
If your device is the heart of your company, clinical data is the lifeblood that sustains its viability before the FDA and investors. We provide robust enforcement of your clinical agreements to ensure that your proprietary information remains secure and your trial progress stays on track. Our focus areas include:
Relying on “standard hospital templates” is a primary cause of clinical failure. We help you avoid:
We don’t just review CTAs; we act as your “Virtual Chief Clinical Counsel.” Our firm understands that for a MedTech startup, every clinical agreement must contribute directly to your FDA clearance and enterprise value.
Decades of High-Stakes Experience: Philip P. Crowley brings the perspective of a counsel who has drawn on decades of experience, including his time as corporate counsel at Johnson & Johnson.
Crowley Law LLC combines decades of corporate legal experience with personalized counsel tailored to the unique needs of startups. The firm is led by Philip P. Crowley, with over 45 years of experience, including prior service as corporate counsel at Johnson & Johnson, where he managed complex internal governance and licensing matters.
Crowley Law LLC focuses on providing strategic, practical advice that helps founders and partners build strong structures, resolve conflicts, and navigate growth smoothly.
Not necessarily. If your device is classified as a “Significant Risk” (SR) device, you must secure an approved IDE from the FDA in addition to local IRB approval before beginning the trial.
Data ownership is dictated by your Clinical Trial Agreement (CTA). Research institutions often use default templates that claim joint or full ownership. We actively negotiate these terms to ensure the sponsor (you) retains full ownership of the data.
Without a specific “Invention Assignment” clause in your CTA, the doctor or the hospital could potentially claim rights to that new application. We structure agreements so that those intellectual property rights flow back to your company.
An FDA IDE is not explicitly required for OUS trials. However, if you intend to use that foreign clinical data to support a future US FDA submission, the trial must be conducted in accordance with recognized international standards (such as the Declaration of Helsinki) and FDA guidelines for foreign data acceptance.
A CTA is the legally binding contract between your company (the sponsor) and the institution conducting the trial. It governs the rules of the study, covering critical issues such as data rights, IP ownership, publication timelines, confidentiality, and indemnification.
